Shopping Cart
- Remove All
- Your shopping cart is currently empty
L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $134 | In Stock | |
2 mg | $198 | In Stock | |
5 mg | $297 | In Stock | |
10 mg | $453 | In Stock | |
25 mg | $769 | In Stock | |
50 mg | $995 | In Stock | |
100 mg | $1,450 | In Stock | |
1 mL x 10 mM (in DMSO) | $297 | In Stock |
Description | L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor. |
In vitro | L524-0366 mitigated maladaptive remodeling with TAC. TWEAK induced secretion of the pro-inflammatory chemokine, monocyte chemoattractant protein 1 from WT but not Fn14-/-?fibroblasts in vitro, in part through activation of non-canonical NF-κB signaling. Finally, Fn14 expression was increased in mouse following TAC and in human failing hearts. |
Cell Research | Wild type (WT) and Fn14 knock out (Fn14-/-) mice were subjected to pressure overload [transaortic constriction (TAC)] for 1 or 6 weeks. A subset of WT TAC animals were treated with the Fn14 antagonist L524-0366. Cardiac function was measured by echocardiography. Cardiac fibrosis and macrophage infiltration were quantified using immunohistochemistry and flow cytometry, respectively. Cardiac fibroblasts were isolated for quantifying TWEAK-induced chemokine release. |
Alias | [1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone |
Molecular Weight | 308.79 |
Formula | C13H13ClN4OS |
Cas No. | 951612-19-4 |
Smiles | C(=O)(C1=CN(N=N1)C2=CC(Cl)=CC=C2)N3CCSCC3 |
Relative Density. | no data available |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 25 mg/ml (80.96 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
In Vivo Formulation | 5% DMSO+95% Corn oil: 1 mg/mL (3.24 mM), Suspension. In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.